Valisure’s Benzene Testing Challenged By PCPC; FDA Focus Should Be Raw Materials, Trade Group Says
Executive Summary
On roughly the 1-year anniversary of Valisure’s citizen petition to the FDA regarding benzene detected in body sprays, the Personal Care Products Council weighs in on the matter.
You may also be interested in...
Ranitidine Cancer Risk Found Only By Litigation Plaintiffs’ ‘Unreliable’ Research, Judge Rules
Plaintiffs in Multi-District Litigation didn’t provide scientific evidence of OTC heartburn drug Zantac increasing risk of cancer. Federal judge says plaintiffs' research showed “a lack of substantiation for analytical leaps” in alleging dangerously high levels of NDMA in ranitidine drugs.
Valisure Alerts US FDA To Benzene In Dry Shampoos, Says Any Detected Level Could Be ‘Unacceptable’
Valisure found 70% of 148 tested dry shampoo batches contained ‘quantifiable’ benzene. The US FDA advises a strict 2ppm limit when benzene’s use is unavoidable to produce a drug product with a “significant therapeutic advance.” In dry shampoos, “any significant detection of benzene could be deemed unacceptable,” Valisure suggests in its 31 October citizen petition to the agency.
Benzene Suits Against US Personal-Care Firms Appear Headed In One Direction: Settlement
The latest in litigation against Unilever, P&G, Beiersdorf and J&J alleging violations for selling personal-care products contaminated with benzene.